Related Experiment Video
Updated: Nov 22, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.3K
Pharmacogenetics Update on Biologic Therapy in Psoriasis.
Ester Muñoz-Aceituno1, Luisa Martos-Cabrera1, María Carmen Ovejero-Benito2
1Dermatology Department, Hospital Universitario de la Princesa, 28006 Madrid, Spain.
Medicina (Kaunas, Lithuania)
|January 9, 2021
Summary
Pharmacogenetics research explores genetic markers for psoriasis treatment response. The HLA-C*06:02 allele shows promise for predicting ustekinumab efficacy, while anti-IL17 drug responses require further investigation.
Area of Science:
- Immunodermatology
- Pharmacogenetics
- Genetics
Background:
- Psoriasis is a chronic, immune-mediated skin disease with complex genetic and environmental factors.
- Biological therapies offer effective psoriasis treatment but exhibit significant inter-individual efficacy variability.
- Personalized therapeutic decisions necessitate biomarkers for predicting treatment outcomes.
Purpose of the Study:
- To review pharmacogenetics studies on moderate-to-severe psoriasis treatment.
- To focus on anti-interleukin (IL)-12/23 (ustekinumab), anti-IL17 (secukinumab, ixekizumab), and anti-TNF drugs.
- To identify genetic variations influencing drug response in psoriasis patients.
Main Methods:
- Literature review of pharmacogenetics studies.
- Analysis of studies on anti-TNF, anti-IL-12/23, and anti-IL-17 therapies.
- Examination of genetic polymorphisms, including genome-wide association studies (GWAS).
Main Results:
- Multiple polymorphisms studied for anti-TNF drug response, with recent GWAS and regimen optimization studies.
- Various gene polymorphisms linked to ustekinumab response, notably the HLA-C*06:02 allele.
- Most studies indicate a higher ustekinumab response rate in patients with the HLA-C*06:02 allele.
Conclusions:
- The HLA-C*06:02 allele is a potential biomarker for ustekinumab response in psoriasis.
- No significant associations found between studied polymorphisms and anti-IL-17 drug (secukinumab) response.
- Larger cohort studies are required to validate findings and implement biomarkers in clinical practice.
Related Concept Videos
01:24Dosage Regimen: Individualization
73
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
73
01:20Measurement of Bioavailability: Pharmacodynamic Methods
85
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
85
01:28Drug Products: Biologics, Biosimilars and Interchangeables
118
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
118
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
437
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
437
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
59
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
59
01:19Factors Affecting Drug Biotransformation: Biological
388
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
388